MYLUNG Consortium Study Protocol 2

Active, not recruitingOBSERVATIONAL
Enrollment

1,002

Participants

Timeline

Start Date

December 29, 2020

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (18)

12208

New York Oncology Hematology, P.C., Albany

20904

Maryland Oncology Hematology, P.A., Silver Spring

22031

Virginia Cancer Specialists, PC, Fairfax

23606

Virginia Oncology Associates, Newport News

32503

Woodlands Medical Specialists, PA, Pensacola

36526

Southern Cancer Center, PC, Daphne

45242

Oncology Hematology Care Clinical Trials, LLC, Cincinnati

55404

Minnesota Oncology Hematology, P.A., Minneapolis

60714

Illinois Cancer Specialists, Niles

75231

Texas Oncology-Dallas Presbyterian Hospital, Dallas

75246

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

75702

Texas Oncology- Northeast Texas, Tyler

76012

Texas Oncology- DFWW, Arlington

76104

Texas Oncology - Fort Worth Cancer Center, Fort Worth

78503

Texas Oncology-McAllen, McAllen

79606

Texas Oncology - West Texas, Abilene

80218

Rocky Mountain Cancer Center, Denver

97401

Willamette Valley Cancer Institute and Research Center, Eugene

All Listed Sponsors
lead

US Oncology Research

INDUSTRY